{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:16:08Z","timestamp":1792430168225,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    In the United States, 40\u201350% of patients with atopic dermatitis (AD) have moderate-to-severe disease, often necessitating advanced systemic therapies (ASTs; biologics or Janus kinase inhibitors). TARGET-DERM AD is an observational, longitudinal registry that tracks the natural history and treatment of AD, including patients with moderate-to-severe disease. Among enrollees, we defined 4 patient subgroups: AST-Na\u00efve, AST-Retrospective (AST initiated prior to enrollment), AST-Prospective (AST initiated at or after enrollment), and AST-Failed (failed at any point). This analysis describes AST-patient demographics, treatment patterns, and longitudinal outcomes. Of 598 qualifying participants (22% adolescent, 78% adult), 34% were AST-Naive, 27% AST-Retrospective, 31% AST-Prospective, and 8% AST-Failed. Comparing the adult subgroups showed significant differences in enrollment age, and race\/ethnicity, but not among adolescents. There was no significant difference in AST prescription rates. Literature-based validated thresholds were used to define unchanged or worsening for each outcome, which was combined into a single category, \u201clacked improvement.\u201d At 52 weeks of AST, AST-Prospective adolescents lacked improvement on Validated Investigator\u2019s Global Assessment of Atopic Dermatitis (vIGA-AD) (26%), body surface area (BSA) (34%), Numeric Rating Scale (NRS)-Pain (63%), and NRS-Sleep (52%); AST-Prospective adults lacked improvement on vIGA-AD (21%), BSA (51%), NRS-Pain (66%), and NRS-Sleep (60%). As one-third of participants did not progress to AST, and noteworthy proportions of patients lacked improvement, this study highlights unmet needs and treatment inadequacies in patients with moderate-to-severe AD.\n                  <\/jats:p>","DOI":"10.1089\/derm.2024.0191","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:52:07Z","timestamp":1739965927000},"page":"244-257","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry"],"prefix":"10.1177","volume":"36","author":[{"given":"Dawn Z.","family":"Eichenfield","sequence":"first","affiliation":[{"name":"From the,  Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-7363","authenticated-orcid":false,"given":"Keith D.","family":"Knapp","sequence":"additional","affiliation":[{"name":"Target RWE, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Claxton","sequence":"additional","affiliation":[{"name":"LEO Pharma, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breda","family":"Munoz","sequence":"additional","affiliation":[{"name":"Target RWE, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Target RWE, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Balu","sequence":"additional","affiliation":[{"name":"LEO Pharma, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[{"name":"LEO Pharma, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schneider","sequence":"additional","affiliation":[{"name":"LEO Pharma, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Haft","sequence":"additional","affiliation":[{"name":"From the,  Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, George Washington University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"From the,  Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[{"name":"Eczema Treatment Center of New Jersey, East Windsor, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie W.","family":"Rhoads","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah Health Hospitals and Clinics, Murry, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of TARGET-DERM AD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18643"},{"issue":"1","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1067\/mjd.2001.117010","article-title":"Quality of life in atopic dermatitis","volume":"45","author":"Finlay AY","year":"2001","unstructured":"Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol. 2001; 45(1 Suppl):S64\u2013S66; doi: 10.1067\/mjd.2001.117010","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000370226"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039928"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15641"},{"issue":"1","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jdv.16846","article-title":"Measurement properties of the product of investigator\u2019s global assessment and body surface area in children and adults with atopic dermatitis","volume":"35","author":"Silverberg JI","year":"2021","unstructured":"Silverberg JI, , Lei D, , Yousaf M, et al. Measurement properties of the product of investigator\u2019s global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2021; 35(1):180\u2013187; doi: 10.1111\/jdv.16846","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjd.21615","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): A clinical outcome measure for the severity of atopic dermatitis","volume":"187","author":"Simpson EL","year":"2022","unstructured":"Simpson EL, , Bissonnette R, , Paller AS, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): A clinical outcome measure for the severity of atopic dermatitis. Br J Dermatol. 2022; 187(4):531\u2013538; doi: 10.1111\/bjd.21615","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaad.2020.01.023","article-title":"Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children","volume":"82","author":"Suh TP","year":"2020","unstructured":"Suh TP, , Ramachandran D, , Patel V, et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. J Am Acad Dermatol. 2020; 82(5):1187\u20131194; doi: 10.1016\/j.jaad.2020.01.023","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1513"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000245677"},{"key":"e_1_3_2_16_2","unstructured":"PROMIS. Itch Scoring Manual. 2022. p. 7."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2014.05.010"},{"key":"e_1_3_2_18_2","volume-title":"University N. PROMIS\u00ae Score Cut Points","year":"2023","unstructured":"University N. PROMIS\u00ae Score Cut Points. HealthMeasures; 2023."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_3_2_20_2","volume-title":"Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-Severe Atopic Dermatitis (AD)","author":"Health CAfDaTi","year":"2018","unstructured":"Health CAfDaTi. Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-Severe Atopic Dermatitis (AD). Health CAfDaTi: Ottawa (ON); 2018."},{"issue":"1","key":"e_1_3_2_21_2","first-page":"147","article-title":"Clinical meaning of change in Dermatology Life Quality Index scores","volume":"1","author":"Khilji FA","year":"2002","unstructured":"Khilji FA, , Gonzalez M, , Finlay A. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol. 2002; 1(1):147.","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02719.x"},{"issue":"6","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"AB93","DOI":"10.1016\/j.jaad.2017.04.376","article-title":"Defining a responder on the Peak Pruritus Numerical Rating Scale (NRS) in patients with moderate-to-severe atopic dermatitis: Detailed analysis from randomized trials of dupilumab","volume":"76","author":"Simpson E","year":"2017","unstructured":"Simpson E, , Beck L, , Gadkari A, et al. Defining a responder on the Peak Pruritus Numerical Rating Scale (NRS) in patients with moderate-to-severe atopic dermatitis: Detailed analysis from randomized trials of dupilumab. Journal of the American Academy of Dermatology. 2017; 76(6):AB93; doi: 10.1016\/j.jaad.2017.04.376","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1967267"},{"issue":"11","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112927","article-title":"Atopic dermatitis: Clinical aspects and unmet needs","volume":"10","author":"Lobefaro F","year":"2022","unstructured":"Lobefaro F, , Gualdi G, , Di Nuzzo S, et al. Atopic dermatitis: Clinical aspects and unmet needs. Biomedicines. 2022; 10(11); doi: 10.3390\/biomedicines10112927","journal-title":"Biomedicines"},{"issue":"11","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg JI","unstructured":"Silverberg JI, , Gooderham M, , Katoh N, et al. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. n\/a; 38(11):2139\u20132148; doi: 10.1111\/jdv.20229","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2024.0191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:09:03Z","timestamp":1777399743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2024.0191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,1]]}},"alternative-id":["10.1089\/derm.2024.0191"],"URL":"https:\/\/doi.org\/10.1089\/derm.2024.0191","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}